Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan in Leptomeningeal Metastases From Solid Tumors
NCT07833657Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in leptomeningeal metastasis (LM), solid tumor. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
leptomeningeal metastasis (LM)solid tumor
Beyond the preview
Go deeper on NCT07833657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833657.